Anti-TNF before or after hemicolectomy with perianal fistula
In CD with active perianal fistula and planned right hemicolectomy, is preoperative anti‑TNF or deferral of biologic until after surgery preferred for reducing postoperative recurrence
Out of scope for this tool. The focus of this literature tool is the surgical management of IBD. For medical management and drug dosing, please see ChatIBD.com.
anti-TNF agents are the most effective medications for preventing postoperative recurrence after ileocolonic resection, but the retrieved evidence supports this as postoperative prophylaxis targeted to high-risk patients, not as a preoperative recurrence-reduction strategy 1,2. On preoperative timing, the concern is infectious-complication risk: several studies linked preoperative anti-TNF to increased infectious complications, though the largest prospective study found no deleterious effect 1. The excerpts do not establish that giving anti-TNF before rather than after this operation reduces recurrence. 1–3
What is known:
- Network meta-analyses confirm anti-TNF agents are the most effective drugs to prevent postoperative recurrence, but prophylaxis is reserved for high-risk patients (smoking, penetrating disease, multiple operations). 1
- Meta-analyses confirm anti-TNF efficacy in preventing postoperative recurrence; mean endoscopic recurrence at 6-12 months was 29% across 37 studies of 1863 patients. 2
- Several studies report preoperative anti-TNF increased infectious complication risk, though the largest prospective study found no deleterious effect. 1
- Preoperative anti-TNF has been used in selected fistulizing/penetrating cases to reduce inflammation and limit resection extent, not to reduce recurrence. 3
What is unknown / caveats:
- Preoperative anti-TNF infectious-complication signal is inconsistent across studies vs the largest prospective cohort
- No retrieved study directly compares preoperative vs postoperative anti-TNF timing for recurrence risk
- Recurrence-prevention evidence is for ileocolonic resection generally, not specifically the perianal-fistula phenotype
- Perianal fistula management itself is not addressed by these excerpts
- Whether preoperative dosing changes recurrence outcomes cannot be answered from these excerpts. The recurrence benefit is established for postoperative prophylaxis.
References
- [No authors listed]. Perioperative management of ileocecal Crohn's disease in the current era. Expert Rev Gastroenterol Hepatol. 2020;14(9):843-855. PMID: 32729736.
- Gisbert JP, Chaparro M. Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease. Drugs. 2023;83(13):1179-1205. PMID: 37505446.
- Wilhelm P, Kirschniak A, Johannink J, Kaufmann S, Klag T, Wehkamp J, Falch C. Enterocutaneous fistula in severely active Crohn's disease: preoperative anti-TNF alpha treatment to limit bowel resection-report of a case. Int J Colorectal Dis. 2019;34(2):369-373. PMID: 30498853.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.
Reviewer notes